Upregulation of long noncoding RNA LOC100507661 promotes tumor aggressiveness in thyroid cancer

Kim, Daham; Lee, Woo Kyung; Jeong, Seonhyang; Seol, Mi Youn; Kim, Hyunji; Kim, Kyung‐Sup; Lee, Mi Kyung; Lee, Jandee; Jo, Young Suk

doi:10.1016/j.mce.2016.05.002

Cited by 38 publications

(31 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other lncRNAs, the HIT000218960, LOC100507661, ENST00000537266 and ENST00000426615, have also been investigated in TC. They showed to play a role in tumor biology, even if only preliminary results are available (Kim et al, 2016;Xu et al, 2016;. Targeting these lncRNAs may have promising benefits for tumor eradication.…”

Section: Hit000218960 Loc100507661 Enst00000537266 and Enst00000426615mentioning

confidence: 99%

LncRNAs as Potential Therapeutic Targets in Thyroid Cancer

Javed

Shah

Rajabi

et al. 2020

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Thyroid cancer (TC) is the most common cancer of endocrine system. TC can be subdivided into 4 different entities, papillary, follicular, medullary and anaplastic thyroid cancer. Among them, anaplastic thyroid cancer has the poorest prognosis. Exploring new therapeutic approach may entail favorable prediction as well as increasing overall survival rate of patients. Long non-coding RNAs (lncRNAs), have vast implications in different cancer types. Although they are not transcribed into proteins, they can act as a harness in regulating a plethora of biological functions. They have been implicated in a decisive role in gene expression via modulation of both coding and non-coding RNAs. This article discuss the multi-facet role of lncRNA in thyroid cancer biology.

show abstract

Section: Hit000218960 Loc100507661 Enst00000537266 and Enst00000426615mentioning

confidence: 99%

LncRNAs as Potential Therapeutic Targets in Thyroid Cancer

Javed

Shah

Rajabi

et al. 2020

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

show abstract

“…Upon verification of 56 potential cancer-promoting genes from the aforementioned study, Kim et al (2016) finally selected 3 candidate lncRNAs for further functional study. Among those 3 lncRNAs, LOC100507661 has been shown to be strongly overexpressed in thyroid cancer tissues compared to paired normal tissue.…”

Section: Loc100507661mentioning

confidence: 99%

Long noncoding RNAs: emerging players in thyroid cancer pathogenesis

Murugan

Munirajan

Alzahrani

2018

Endocrine-Related Cancer

111

103

View full text Add to dashboard Cite

Thyroid cancer continues to be the most common malignancy of endocrine glands. The incidence of thyroid cancer has risen significantly over the past 4 decades and has emerged as a major health issue. In recent years, significant progress has been achieved in our understanding of the molecular mechanisms of thyroid carcinogenesis, resulting in significant diagnostic, prognostic and therapeutic implications; yet, it has not reached a satisfactory level. Identifying novel molecular therapeutic targets and molecules for diagnosis and prognosis is expected to advance the overall management of this common malignancy. Long noncoding RNAs (lncRNAs) are implicated in the regulation of various key cellular genes involved in cell differentiation, proliferation, cell cycle, apoptosis, migration and invasion mainly through modulation of gene expression. Recent studies have established that lncRNAs are deregulated in thyroid cancer. In this review, we discuss extensively the tumor-suppressive (for example, LINC00271, MEG3, NAMA, PTCSC1/2/3, etc.) and oncogenic (for example, ANRIL, FAL1, H19, PVT1, etc.) roles of various lncRNAs and their possible disease associations implicated in thyroid carcinogenesis. We briefly summarize the strategies and mechanisms of lncRNA-targeting agents. We also describe the potential role of lncRNAs as prospective novel therapeutic targets, and diagnostic and prognostic markers in thyroid cancer.

show abstract

“…lncRNAs respectively, which lay the foundation for further investigation of lncRNAs related to PTC [26,27]. In addition, important regulatory mechanisms of lncRNAs in the process of tumorigenesis, progression, proliferation, metastases, apoptosis and autophagy of PTC have been reported [27][28][29][30][31][32]. BRAF-activated lncRNA (BANCR) could activate autophagy [28] and inhibit tumorigenesis in PTC and its levels might be used as a novel prognostic marker [29].…”

Section: Discussionmentioning

confidence: 99%

“…lncRNAs (ENST00000426615 and ENST00000537266) might be important regulators of PTC cell proliferation and motility [31]. LncRNA (LOC100507661) expression was elevated in human thyroid cancer tissue and might play a critical role in thyroid carcinogenesis [32]. LncRNA (ANRIL) might reduce p15…”

Section: Discussionmentioning

confidence: 99%

Circulating Long Non-Coding RNAs Act as Biomarkers for Predicting 131I Uptake and Mortality in Papillary Thyroid Cancer Patients with Lung Metastases

Qiu

Shen²,

Sun³

et al. 2016

Cell Physiol Biochem

View full text Add to dashboard Cite

Purpose: The aims of the current study were to explore plasma lncRNAs as a novel biomarker panel for the diagnosis of non-¹³¹I-avid lung metastases of PTC and to investigate the plasma lncRNA expression levels associated with survival in PTC patients with lung metastases. Methods: The expression of lncRNAs was examined using an lncRNA microarray chip. The lncRNAs with the most significant difference in expression between PTC patients with non-¹³¹I-avid lung metastases and PTC patients with ¹³¹I-avid lung metastases were verified by quantitative reverse-transcription polymerase chain reaction. The Kaplan-Meier method was used to determine whether the plasma lncRNA levels might be indicative of patient prognosis. Results: Compared with ¹³¹I-avid lung metastases, we discovered that two lncRNAs (ENST00000462717 andENST00000415582) were upregulated and two (TCONS_00024700 and NR_028494) were downregulated in the non-¹³¹I-avid lung metastases of PTC. Receiver operating characteristic curve (ROC) analyses indicated that the use of these four lncRNAs had high diagnostic sensitivity and specificity for predicting non-¹³¹I-avid lung metastases of PTC. The merged areas under the curve for ENST00000462717, ENST00000415582, TCONS_00024700,and NR_028494 in the training and validation sets were 0.890, 0.936, 0.975, and 0.918, respectively. Low (ENST00000462717 and ENST00000415582) and high plasma lncRNA levels(TCONS_00024700and NR_028494) were also found to be associated with better prognosis of PTC patients with lung metastases(P<0.001). Conclusions: ENST00000462717, ENST00000415582, TCONS_00024700, and NR_028494 may be used as novel and minimally invasive markers for the diagnosis and prognostic assessment of non-¹³¹I-avid lung metastases from PTC.

show abstract

Upregulation of long noncoding RNA LOC100507661 promotes tumor aggressiveness in thyroid cancer

Cited by 38 publications

References 35 publications

LncRNAs as Potential Therapeutic Targets in Thyroid Cancer

LncRNAs as Potential Therapeutic Targets in Thyroid Cancer

Long noncoding RNAs: emerging players in thyroid cancer pathogenesis

Circulating Long Non-Coding RNAs Act as Biomarkers for Predicting 131I Uptake and Mortality in Papillary Thyroid Cancer Patients with Lung Metastases

Contact Info

Product

Resources

About